OSE Pharma SA (PA:OSE) — Market Cap & Net Worth
Market Cap & Net Worth: OSE Pharma SA (OSE)
OSE Pharma SA (PA:OSE) has a market capitalization of $82.83 Million (€70.85 Million) as of August 5, 2026. Listed on the PA stock exchange, this France-based company holds position #19819 globally and #306 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OSE Pharma SA's stock price €3.16 by its total outstanding shares 22420176 (22.42 Million). See OSE Pharma SA capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
OSE Pharma SA Market Cap History: 2015 to 2026
OSE Pharma SA's market capitalization history from 2015 to 2026. Data shows change from $222.01 Million to $82.83 Million (-9.44% CAGR).
Index Memberships
OSE Pharma SA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$231.52 Billion | 0.04% | #92 of 119 |
|
CAC Small90
CACS
|
$36.96 Billion | 0.22% | #42 of 64 |
|
CAC All-Tradable
CACT
|
$2.86 Trillion | 0.00% | #152 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.86 Trillion | 0.00% | #152 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.86 Trillion | 0.00% | #152 of 179 |
|
CAC Health Care
FRHC
|
$253.47 Billion | 0.03% | #26 of 36 |
Weight: OSE Pharma SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OSE Pharma SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OSE Pharma SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.69x
OSE Pharma SA's market cap is 2.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.02x
OSE Pharma SA's market cap is 5.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $222.01 Million | $4.00K | -$5.58 Million | 55502.94x | N/A |
| 2016 | $185.58 Million | $383.00K | $20.67 Million | 484.54x | 8.98x |
| 2017 | $100.91 Million | $6.68 Million | -$10.50 Million | 15.10x | N/A |
| 2018 | $89.12 Million | $24.46 Million | $5.49 Million | 3.64x | 16.23x |
| 2019 | $96.98 Million | $25.95 Million | -$4.65 Million | 3.74x | N/A |
| 2020 | $188.72 Million | $10.42 Million | -$16.55 Million | 18.12x | N/A |
| 2021 | $269.45 Million | $26.31 Million | -$16.85 Million | 10.24x | N/A |
| 2022 | $174.96 Million | $18.30 Million | -$17.76 Million | 9.56x | N/A |
| 2023 | $112.19 Million | $2.23 Million | -$23.00 Million | 50.38x | N/A |
| 2024 | $187.94 Million | $69.88 Million | $37.45 Million | 2.69x | 5.02x |
Competitor Companies of OSE by Market Capitalization
Companies near OSE Pharma SA in the global market cap rankings as of August 5, 2026.
Key companies related to OSE Pharma SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
OSE Pharma SA Historical Marketcap From 2015 to 2026
Between 2015 and today, OSE Pharma SA's market cap moved from $222.01 Million to $ 82.83 Million, with a yearly change of -9.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €82.83 Million | -38.64% |
| 2025 | €134.99 Million | -28.17% |
| 2024 | €187.94 Million | +67.52% |
| 2023 | €112.19 Million | -35.88% |
| 2022 | €174.96 Million | -35.07% |
| 2021 | €269.45 Million | +42.78% |
| 2020 | €188.72 Million | +94.59% |
| 2019 | €96.98 Million | +8.82% |
| 2018 | €89.12 Million | -11.69% |
| 2017 | €100.91 Million | -45.62% |
| 2016 | €185.58 Million | -16.41% |
| 2015 | €222.01 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of OSE Pharma SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $82.83 Million USD |
| MoneyControl | $82.83 Million USD |
| MarketWatch | $82.83 Million USD |
| marketcap.company | $82.83 Million USD |
| Reuters | $82.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OSE Pharma SA
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more